Compare Amazon.com Inc (AMZN) vs TG Therapeutics Inc (TGTX) Price & Performance

Amazon (AMZN) trades at $272.27, down 2.09% today but maintains strong fundamentals with robust revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Technical indicators show a bullish trend with support at $271 and resistance at $275, while analyst consensus remains overwhelmingly positive with 89% buy ratings and a $333.86 price target. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS growth and AI chip business expansion.

Amazon presents a compelling investment case with accelerating profitability and dominant market positioning, though investors face risks from intense competition and significant capital expenditures. The stock's current valuation at 21.9x P/E appears reasonable given projected 2026 net income growth to $135.3B, supporting potential upside to analyst targets despite near-term market volatility.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.